OxSyBio has created technology to 3D-print tissue-like synthetic materials for medical research and clinical applications.
OxSyBio, a UK-based 3D bioprinting spinout from University of Oxford, secured an undisclosed amount yesterday from investors including Parkwalk Advisors, the fund manager owned by commercialisation firm IP Group.
IP Group previously provided OxSyBio with an initial investment of $1.7m, subject to milestones, when the spinout launched in 2014.
OxSyBio has developed a 3D-printing technique capable of producing human cell-like structures which are protected by nanolitre-sized droplets and lipid coating to help prevent them from collapsing in on themselves – mimicking…
